EGFR-mutated, metastatic pulmonary pleomorphic carcinoma successfully treated with afatinib
Pulmonary pleomorphic carcinoma (PPC) has an aggressive clinical course and poor prognosis mainly because of the difficulty in achieving therapeutic effects. Despite a small fraction of patients with PPC possessing an epidermal growth factor receptor (EGFR) activating mutation, only a limited number...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-06-01
|
Series: | Current Problems in Cancer: Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621922000242 |